LLY at a glance
Lilly (Eli) (LLY, SEC CIK 59478) filed its latest 10-K annual report on February 12, 2026, a 10-Q quarterly report on October 29, 2026, an 8-K current report on October 29, 2026 and Form 4 insider filings as recently as November 17, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Lilly (Eli) (LLY) reported revenue of $65.2 billion (up 44.7% from FY2024) and net income of $20.6 billion. Diluted EPS was $22.95.
- As of September 30, 2026, 74 institutional investment managers tracked by SignalX reported holding Lilly (Eli) (LLY) shares worth $393.1 billion in 13F-HR filings.
- In the last 90 days, LLY insiders reported 0 open-market purchases ($0) and 1 open-market sale ($7.0M) on Form 4, a net sale of $7.0M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $65.2B
- +44.7% vs prior year
- Insiders · 90 days
- 0 buys · 1 sell
- Net −$7.0M
- 13F holders
- 74 funds
- $393.1B · −3 vs prior quarter
- Latest 8-K
- Oct 29, 2026
- Item 2.02
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business: Discovery, development, manufacturing, and marketing of human pharmaceutical products globally
- New emphasis on LillyDirect digital platform, growing portion of sales in 2025, expanding direct-to-patient access and partnerships
- Strategic shift to alternative product access via direct-to-patient and direct-to-employer channels to counteract unfavorable private sector payer dynamics
- Patent protection extends key products like Mounjaro to 2036-2040, with multiple patent term extensions and biologics data exclusivity through 2030s
- Noteworthy regulatory and market risk from counterfeit, misbranded, adulterated, and mass-compounded incretin products impacting safety and market integrity
Risk Factors
- Government price controls per Inflation Reduction Act causing Medicare drug price reductions for Jardiance (2026) and Trulicity, Verzenio (2028), accelerating revenue erosion
- U.S. market access risk from CVS Caremark removing preferred coverage for Zepbound on some insurance plans in July 2025
- Supply chain concentration with U.S. distribution reliant on limited wholesalers, risking disruptions if key wholesalers fail or delay payments
- Intense competition from multinational and Chinese pharmaceutical companies with accelerating R&D capabilities impacting market share and pricing
- Intellectual property risk from imminent patent expirations on key drug Trulicity and generic/biosimilar competition causing rapid revenue declines
Management Discussion & Analysis
- Revenue $65.2B in 2025, up 45% YoY from $45.0B in 2024, driven by Mounjaro and Zepbound volume growth
- Gross margin 83.0% in 2025 vs 81.3% in 2024; net income $20.6B (+95% YoY), EPS $22.95 (+96%)
- Best segment: Mounjaro revenue $23.0B (+99%) including $13.7B U.S.; worst segment: Other products down 1% to $22.9B
- Operating cash flow $16.8B in 2025 vs $8.8B prior year; capex $7.8B vs $5.1B; dividends $3.0B paid ($6/share); share repurchases $4.1B under $15B program
- Management expects near-term impact from regulatory approvals and U.S. Medicare access timing; key risks include evolving drug pricing policies and global trade tensions impacting margins and revenue
AI summary of the LLY 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- No material changes from the December 31, 2025 Form 10-K risk factors
- Carried-forward risks remain the company’s material disclosed exposures
Management Discussion & Analysis
- Revenue $24,397M, up $6,796M YoY from $17,601M, driven by volume despite lower realized prices
- Gross margin 83.9% vs 82.9% YoY, with gross margin dollars of $20,464M vs $14,593M
- Best performer: Mounjaro revenue $10,723M vs $6,515M, up 64% YoY
- Cash $4.9B vs $7.3B at December 31, 2025, with $18.2B deployed to business development
- Near-term risks: Medicare uptake uncertainty, pricing pressure, counterfeit incretins, and additional manufacturing investment needs
AI summary of the LLY 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q3 2026 financial results for quarter ended September 30, 2026
- Results announced in Eli Lilly’s October 29, 2026 press release, Exhibit 99.1
Item EX-99.1: Item EX-99.1
- Q3 revenue $24.4B, up 39%, led by Mounjaro $10.7B and Zepbound $5.4B
- Volume rose 53%, while realized prices fell 15%, highlighting strong demand but increasing pricing pressure
Item EX-99.1: Item EX-99.1
- Q2 revenue $22.974B, up 48%, with volume up 60% despite realized-price decline of 13%
- Mounjaro revenue $9.943B, up 91%, and Zepbound revenue $4.928B, up 46%, reinforcing incretin concentration
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 financial results announced for the quarter ended June 30, 2026
- Exhibit 99.1 contains the earnings release and the company’s reported operating results
Item 8.01: Other Events
- $9.0B debt offering completed, generating approximately $8.94B net proceeds for corporate funding
- Debt spans floating-rate notes due 2028–2029 and fixed-rate notes due 2029–2066
AI summaries of LLY 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for LLY
Don't miss the next LLY filing
- Alerts as it files. A push when LLY files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut LLY, by share count.
- Ask anything. An AI agent that reads every LLY filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Fyrwald J Erik | A | Nov 16, 2026 | 167.636 | $1431.67 |
| Alvarez Ralph | A | Nov 16, 2026 | 167.636 | $1431.67 |
| LUCIANO JUAN R | A | Nov 16, 2026 | 167.636 | $1431.67 |
| Fyrwald J Erik | A | Nov 16, 2026 | 6.927 | $1431.67 |
| Sulzberger Gabrielle | A | Nov 16, 2026 | 167.636 | $1431.67 |
| Alvarez Ralph | A | Nov 16, 2026 | 8.673 | $1431.67 |
| LUCIANO JUAN R | A | Nov 16, 2026 | 11.118 | $1431.67 |
| Sulzberger Gabrielle | A | Nov 16, 2026 | 3.463 | $1431.67 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|
| Profitability | ||||
| Revenue | $34.1B | $45.0B | $65.2B | |
| Net Income | $5.2B | $10.6B | $20.6B | |
| Net Margin | 15.4% | 23.5% | 31.7% | |
| Balance Sheet | ||||
| Total Assets | $64.0B | $78.7B | $112.5B | |
| Equity | $10.8B | $14.2B | $26.5B | |
| ROE | 48.6% | 74.6% | 77.8% | |
| Per Share | ||||
| EPS | $5.80 | $11.71 | $22.95 | |
| Cash Flow | ||||
| Operating CF | $4.2B | $8.8B | $16.8B | |
Source: XBRL data in Lilly (Eli) (LLY)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate LLY share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 74 | $393.13B |
| Q2 2026 | 77 | $439.72B |
| Q1 2026 | 76 | $330.72B |
| Q4 2025 | 73 | $395.48B |
| Q3 2025 | 75 | $287.80B |
| Q2 2025 | 74 | $290.86B |
| Q1 2025 | 72 | $279.58B |
| Q4 2024 | 69 | $187.28B |
- JPMorgan Chase & Co+1.19M (+9%)
- State Street Corp+632.8K (+2%)
- BlackRock+395.8K (+1%)
- Vanguard Capital Management LLC+392.3K (+1%)
- Two Sigma Investments+258.0K (+318%)
- Goldman Sachs Group−793.8K (-10%)
- Franklin Resources−703.3K (-15%)
- T. Rowe Price Group−528.5K (-4%)
- Citadel Advisors LLC−264.0K (-28%)
- Bank of America Corp−244.7K (-2%)
- FMR LLC (Fidelity)−28.46M
- Equitable Holdings Inc−45.8K
- Northwest Bancshares, Inc.−2.6K
Source: 13F-HR filings on SEC EDGAR (aggregated from 590 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
LLY filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
8-K current reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 17, 2026 | - | - | - |
| 4 | Nov 17, 2026 | - | - | - |
| 4 | Nov 17, 2026 | - | - | - |
| 4 | Nov 17, 2026 | - | - | - |
| 4 | Nov 17, 2026 | - | - | - |
| 4 | Nov 17, 2026 | - | - | - |
| 4 | Nov 17, 2026 | - | - | - |
| 4 | Nov 17, 2026 | - | - | - |
| 4 | Nov 17, 2026 | - | - | - |
| 4 | Nov 17, 2026 | - | - | - |
| 4 | Nov 17, 2026 | - | - | - |
| 4 | Nov 10, 2026 | - | - | - |
| 4 | Nov 4, 2026 | - | - | - |
| 4 | Nov 3, 2026 | - | - | - |
| 4 | Nov 3, 2026 | - | - | - |
| 4 | Nov 3, 2026 | - | - | - |
| 4 | Nov 3, 2026 | - | - | - |
| 4 | Nov 3, 2026 | - | - | - |
| 4 | Nov 3, 2026 | - | - | - |
| 4 | Nov 3, 2026 | - | - | - |
| 10-Q | Oct 29, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Oct 29, 2026 | - | Analysis | - |
| 4 | Oct 20, 2026 | - | - | - |
| 4 | Oct 20, 2026 | - | - | - |
| 4 | Oct 20, 2026 | - | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
LLY SEC filings: frequently asked questions
Are LLY insiders buying or selling?
In the last 90 days, Lilly (Eli) (LLY) officers, directors and 10% owners reported no open-market purchases and 1 open-market sale worth $7.0 million by 1 insider on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold LLY stock?
As of September 30, 2026, the largest Lilly (Eli) (LLY) holders among the 13F filers tracked by SignalX were BlackRock ($78.6 billion), Vanguard Capital Management LLC ($62.4 billion), PNC Financial Services ($59.4 billion), State Street Corp ($42.6 billion), Vanguard Portfolio Management LLC ($24.3 billion). 13F-HR reports are filed up to 45 days after each quarter ends.
What was LLY's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Lilly (Eli) (LLY) reported revenue of $65.2 billion (up 44.7% from FY2024) and net income of $20.6 billion. Diluted EPS was $22.95. The figures come from the XBRL data in the 10-K.
What are the main risks in LLY's latest 10-K?
In the 10-K filed February 12, 2026, Lilly (Eli) (LLY) flagged: Government price controls per Inflation Reduction Act causing Medicare drug price reductions for Jardiance (2026) and Trulicity, Verzenio (2028), accelerating revenue erosion. U.S. market access risk from CVS Caremark removing preferred coverage for Zepbound on some insurance plans in July 2025. (AI summary of the Risk Factors section.)
What did LLY report in its latest 8-K?
Lilly (Eli) (LLY) filed an 8-K on October 29, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 2026 financial results for quarter ended September 30, 2026.
What are the latest LLY SEC filings?
Lilly (Eli) (LLY) filed its latest 10-K annual report on February 12, 2026, a 10-Q quarterly report on October 29, 2026, an 8-K current report on October 29, 2026 and a Form 4 insider filing on November 17, 2026.
What is LLY's SEC CIK number?
Lilly (Eli) (LLY)'s SEC Central Index Key (CIK) is 59478. EDGAR lists every LLY filing under that number.
Ask anything about LLY
The research agent reads LLY's filings, financials, insider trades and 13F holders, then answers with sources.